Methods for reducing aggregate content in protein preparations

Patent metadata

Field	Value
Publication number	US-9975919-B2
Application number	US-201414766129-A
Country	US
Kind code	B2
Filing date	Feb 5, 2014
Priority date	Feb 6, 2013
Publication date	May 22, 2018
Grant date	May 22, 2018

Abstract

A method of reducing aggregate and product-contaminant complex content in a protein preparation including a desired protein includes (i) contacting the protein preparation with at least one solid surface comprising at least one surface-bound ligand capable of binding a metal, the surface-bound ligand being capable of binding a metal is initially substantially devoid of a metal, the operating conditions are selected to substantially prevent the binding of the desired protein to the at least one solid surface and (ii) separating the protein preparation from the surface-bound ligand, such that when more than one surface-bound ligand is present, each surface-bound ligand is independently either of the same net charge or charge neutral.

First claim

What is claimed is:

1. A method of reducing aggregate and product-contaminant complex content in a protein preparation comprising an antibody, the method comprising: (a) contacting the preparation with allantoin at a concentration in a range from 0.6% to 50% (w/v), wherein after the contacting of (a), the preparation is supersaturated with the allantoin, (b) contacting the protein preparation with at least a first solid surface comprising a first surface-bound ligand selected from tris(2-aminoethyl)amine (TREN), diethylenetriamine, triethylenetetramine, tetraethylenepentamine, polypropylenimine tetraamine, deferoxamine (desferrioxamine), histidine, histamine, polyhistidine, arginine, polyarginine, lysine, polylysine, and polyallylamine, wherein operating conditions are selected to prevent binding of the antibody to the first solid surface; and (c) separating the protein preparation from the first solid surface; wherein when more than one surface-bound ligand is present, each surface-bound ligand is independently either of the same net charge or charge neutral.

2. The method of claim 1 , wherein the first surface-bound ligand provides further chemical functionality selected from the group consisting of electrostatic interactions, hydrophobic interactions, pi-pi interactions, hydrogen bonding, and combinations thereof.

3. The method of claim 1 , wherein the contacting step further comprises contacting the protein preparation with at least a second surface-bound ligand that provides a chemical functionality that does not bind a metal.

4. The method of claim 3 , wherein the first solid surface comprises the second surface-bound ligand.

5. The method of claim 3 , wherein a second solid surface comprises the second surface-bound ligand and the second solid surface does not substantially interact with the antibody.

6. The method of claim 3 , wherein the chemical functionality that does not bind a metal provides a chemical functionality selected from the group consisting of metal affinity, electrostatic interactions, hydrophobic interactions, pi-pi binding, hydrogen bonding, and combinations thereof.

7. The method of claim 1 , wherein the net charge on the first surface-bound ligand is positive.

8. The method of claim 7 , wherein the first surface-bound ligand is selected from the group consisting of tris(2-aminoethyl)amine (TREN), diethylenetriamine, triethylenetetramine, tetraethylenepentamine, and polypropylenimine tetraamine.

9. The method of claim 1 , wherein the concentration of allantoin is selected from the group consisting of (a) from about 0.6 to about 1%; (b) from about 1 to about 2%; and (c) from about 2 to about 5%.

10. The method of claim 1 , wherein a conductivity of the protein preparation comprises a range of from about 0.1 mS/cm to about 40 mS/cm, or from about 40 mS/cm to about 200 mS/cm.

11. The method of claim 1 , wherein the selected operating conditions comprise a conductivity greater than 20 mS/cm.

12. The method of claim 1 , wherein the selected operating conditions comprise a pH in a range of about 5 to about 9.

13. The method of claim 1 , wherein the first solid surface comprises a particle or a composite of particles, a fiber or composite of fibers, a membrane or composite of membranes or a monolith or composite of monoliths.

14. The method of claim 1 , wherein the contacting further comprises contacting the protein preparation with two or more solid surfaces that are (i) structurally similar to, but distinct from the first solid surface, or (ii) structurally distinct from the first solid surface, and wherein each of the two or more solid surfaces comprise one or more surface-bound ligands different from the first surface-bound ligand.

15. The method of claim 1 , wherein the protein preparation comprises a recombinant antibody.

16. The method of claim 1 , wherein after (c) the protein preparation has a reduced aggregate content, wherein the aggregate content is reduced by an amount in a range selected from the group consisting of (a) from about 50% to about 99%; (b) from about 25% to about 50%; (c) from about 10% to about 25%; (d) from about 5% to about 10%; (e) from about 1% to about 5%; and (f) from about 0.1% to about 1%.

17. The method of claim 1 , further comprising, before (c), contacting the protein preparation with at least one organic additive to reduce aggregate contaminants in the preparation, wherein the organic additive is selected from the group consisting of an electropositive ion, an electronegative ion, an organic solvent, an organic polymer, and a surfactant.

Assignees

• Agency Science Tech & Res

Inventors

• Gagnon Peter Stanley

Classifications

• C07K1/14 Primary

  Extraction; Separation; Purification · CPC title

• B01D15/363

  Anion-exchange · CPC title

• B01D15/3828

  Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography · CPC title

• C07K1/20

  Partition-, reverse-phase or hydrophobic interaction chromatography · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title